Cempra to Present at the Leerink Partners 5th Annual Global Healthcare Conference
February 03, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra and Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement for Solithromycin
February 01, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C. and WATERTOWN, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (NASDAQ:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical...
Cempra to Ring NASDAQ Closing Bell to Mark 10th Anniversary
January 26, 2016 08:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Completes Public Offering of Common Stock
January 12, 2016 16:05 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Prices Public Offering of Common Stock
January 06, 2016 20:42 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at J.P. Morgan Healthcare Conference
January 06, 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Announces Proposed Public Offering of $175 Million of Common Stock
January 05, 2016 16:10 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Doses Initial Patient in Phase 2 Clinical Trial of Solithromycin in NASH
January 05, 2016 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents
December 22, 2015 16:05 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Doses First Patient in Phase 3 Clinical Trial of Taksta(TM) in Acute Bacterial Skin and Skin Structure Infections
December 08, 2015 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company developing antibiotics to meet critical medical needs in the treatment of...